SpringWorks Therapeutics(US:SWTX) Zhi Tong Cai Jing·2025-08-12 00:09Group 1 - Merck KGaA plans to issue approximately $4 billion in U.S. investment-grade bonds to finance the acquisition of SpringWorks Therapeutics [1] - The bond issuance will be divided into up to four tranches with maturities of three, five, seven, and ten years [1] - The proceeds from the bond issuance will be used to refinance the $3.9 billion temporary debt incurred from the acquisition [1] Group 2 - SpringWorks Therapeutics' core assets include two FDA-approved first-in-class drugs: OGSIVEO (nirogacestat) for treating adult progressive desmoid tumors and GOMEKLI (mirdametinib) for neurofibromatosis type 1-related plexiform neurofibromas [2] - OGSIVEO is the first systemic standard therapy for a condition that previously lacked effective medication, while GOMEKLI fills a decades-long gap in treatment options for patients aged two and above [2] - The acquisition allows Merck to enter the U.S. market, the largest pharmaceutical market globally, and leverage its commercial network to accelerate the drugs' entry into Europe and Asia [2]